Edwards Lifesciences Corp (EW)vsInfuSystems Holdings Inc (INFU)
EW
Edwards Lifesciences Corp
$105.80
-0.01%
HEALTHCARE · Cap: $59.81B
INFU
InfuSystems Holdings Inc
$14.79
-1.92%
HEALTHCARE · Cap: $261.91M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 4557% more annual revenue ($6.67B vs $143.34M). EW leads profitability with a 15.3% profit margin vs 6.0%. INFU appears more attractively valued with a PEG of 1.73. INFU earns a higher WallStSmart Score of 56/100 (C).
EW
Buy54
out of 100
Grade: C-
INFU
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$105.80
$151.68 discount
Margin of Safety
+27.7%
Fair Value
$10.53
Current Price
$14.79
$4.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Earnings expanding 25.0% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Premium valuation, high expectations priced in
2.6% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bull Case : INFU
The strongest argument for INFU centers on EPS Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Bear Case : INFU
The primary concerns for INFU are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
EW profiles as a mature stock while INFU is a value play — different risk/reward profiles.
INFU carries more volatility with a beta of 1.38 — expect wider price swings.
EW is growing revenue faster at 10.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
INFU scores higher overall (56/100 vs 54/100). EW offers better value entry with a 69.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →InfuSystems Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?